Oliver Dorigo, MD, PhD
COMMENTING ON THE study by Cybulska et al, invited discussant Oliver Dorigo, MD, PhD, of Stanford University, said several important questions still need answers. “Tumor immune scores differ between metastatic sites, but how do these immune scores predict response to immunotherapy? And how does mapping of the immune environment affect therapy choices?” he asked. Even after these questions are answered, it will be valuable to be able to assess tumor microenvironments with noninvasive imaging studies in order to capture important differences between metastatic sites, he said. ■
DISCLOSURE: Dr. Dorigo reported no conflicts of interest.
INTER- AND INTRAPATIENT heterogeneity of the tumor microenvironment may explain the limited success of checkpoint blockade thus far observed in patients with advanced high-grade serous ovarian cancer, according to Paulina Cybulska, MD, MSc, of Memorial Sloan Kettering Cancer Center in New York.